Effects of Rosi treatment on ASKO mice.

Slides:

Advertisements

Similar presentations

Fig. 1. SR-202 Is a Specific PPARγ Antagonist A, Structure of SR-202

Advertisements

Fig. 1. Body growth and leptin responsivity in young CPO and CTR mice

Peter L. Lee, Yuefeng Tang, Huawei Li, David A. Guertin

Figure 1 Body weight of control and BPA-treated mothers after delivery

Volume 10, Issue 4, Pages (October 2009)

Volume 20, Issue 3, Pages (July 2017)

Volume 8, Issue 4, Pages (October 2008)

Metabolic effects of K107R and rosiglitazone treatment.

Volume 17, Issue 4, Pages (April 2013)

Volume 18, Issue 2, Pages (August 2013)

Fads2−/− mice develop obesity resistance A–CBody size [cm] (nose‐tail root) and weight of male and female fads2−/− mice (age 4 months) differed by about.

TFE3 prevents diet‐induced obesity and metabolic syndrome

Antidiabetic Effects of IGFBP2, a Leptin-Regulated Gene

Volume 17, Issue 5, Pages (May 2013)

Impaired glucose tolerance in adult S1/3 KO mice on a normal chow

Volume 15, Issue 1, Pages (January 2012)

Volume 14, Issue 2, Pages (August 2011)

Protection against High-Fat-Diet-Induced Obesity in MDM2C305F Mice Due to Reduced p53 Activity and Enhanced Energy Expenditure Shijie Liu, Tae-Hyung.

Antidiabetic Effects of IGFBP2, a Leptin-Regulated Gene

Volume 14, Issue 10, Pages (March 2016)

Volume 17, Issue 8, Pages (November 2016)

Volume 17, Issue 4, Pages (April 2013)

Volume 8, Issue 4, Pages (October 2008)

Volume 25, Issue 4, Pages e4 (April 2017)

Volume 8, Issue 5, Pages (November 2008)

Volume 14, Issue 6, Pages (February 2016)

Mitofusin 2 in Mature Adipocytes Controls Adiposity and Body Weight

Volume 20, Issue 4, Pages (October 2014)

Cellularity of epididymal adipose tissue.

Overexpression of BTG2 resulted in an increase in hepatic gluconeogenesis. Overexpression of BTG2 resulted in an increase in hepatic gluconeogenesis. A:

Deletion of neuronal insulin receptor signaling reduces TG secretion, while the targeted knockout of insulin receptors restricted to the periphery increases.

Glucose, insulin, and AGE levels during an OGC before and after RT

Exogenous CRP administration causes fasting hyperglycemia and hyperinsulinemia without altering body composition. Exogenous CRP administration causes fasting.

WASH cKO mice display a normal pancreatic development.

TG-CRP mice display fasting hyperglycemia, hyperinsulinemia, and insulin resistance. TG-CRP mice display fasting hyperglycemia, hyperinsulinemia, and insulin.

GSIS. GSIS. In vivo: serum insulin levels at fasting state and 30 min after glucose injection (A) and the fold change in serum insulin after glucose loading.

Loss of protection by linagliptin against obesity-related inflammation and insulin resistance in MIP-1α−/− mice. Loss of protection by linagliptin against.

Glucose tolerance in WT and TRPM2-KO mice.

Transgenic restoration of long-chain n-3 PUFA protects against obesity-linked insulin resistance and glucose intolerance. Transgenic restoration of long-chain.

Effect of berberine on white adipose tissue mass.

At 6 months of age, PPARγ deletion in late osteoblast/osteocyte controls glucose homeostasis by increasing metabolic rate and glucose uptake in WAT, BAT,

ΑGLP-1R−/− mice show glucose intolerance and disturbed glucagon secretion in response to i.p. glucose administration. αGLP-1R−/− mice show glucose intolerance.

Effects of the β-cell–specific expression of mKL on blood glucose levels, glucose tolerance, insulin sensitivity, and plasma insulin levels in STZ-induced.

BAFF-deficient (BAFFnull) and anti-BAFF antibody (Ab)–treated obese mice exhibit superior glucose metabolic control compared with WT and Bnull mice. BAFF-deficient.

A: Chemical structure of pterosin A

Chop deletion preserves β-cell function in P58IPK−/− mice.

AgRP-ATF4 KO mice have decreased food intake and enhanced energy expenditure. AgRP-ATF4 KO mice have decreased food intake and enhanced energy expenditure.

USP2–45 regulates hepatic gluconeogenesis.

Effect of anandamide on blood glucose clearance and insulin sensitivity. Effect of anandamide on blood glucose clearance and insulin sensitivity. A: Intraperitoneal.

MϕRIP140KD mice show browning in vWAT.

HFD feeding induced insulin resistance in TRIB3 MOE mice.

Hepatic fuel metabolism in male 5αR1-KO and WT mice

Mice fed GP-SPI diet show improved fasting glucose and oral glucose tolerance. Mice fed GP-SPI diet show improved fasting glucose and oral glucose tolerance.

Hepatic PPARγ deficiency impairs the SCFA-induced reduction in hepatic steatosis. Hepatic PPARγ deficiency impairs the SCFA-induced reduction in hepatic.

Insulin resistance and hepatic steatosis in ASKO mice.

Treatment of high-fat diet–fed mice with TTR-ASOs decreases circulating TTR and RBP4 levels, and improves insulin sensitivity. Treatment of high-fat diet–fed.

Treatment of ob/ob mice with TTR-ASOs improves insulin sensitivity.

MϕRIP140KD mice exhibit improved metabolic phenotypes.

Effects of chow-diet feeding on control and TRIB3 MOE mice.

Urinary albumin excretion and histology of glomeruli.

Metabolic effects of VSG in GLP-1r KO mice.

Glucose-stimulated insulin secretion, plasma glucagon levels, and pancreatic hormone contents. Glucose-stimulated insulin secretion, plasma glucagon levels,

Metabolic outcomes associated with DIO in E3FAD and E4FAD mice.

GTTs and ITTs. A: GTTs of WT (◇), LepTg (♦), Akita (open circles), and LepTg:Akita (closed circles) mice at 8 and 16 weeks of age. GTTs and ITTs. A: GTTs.

High-fat diet–induced glucose intolerance is prevented in ghrelin knockout (Ghr-KO) mice. High-fat diet–induced glucose intolerance is prevented in ghrelin.

Loss of Phb2 in β-cells induces development of diabetes over a 3-week period in β-Phb2−/− mice. Loss of Phb2 in β-cells induces development of diabetes.

Mice lacking Y1 receptor in the hematopoietic compartment remain healthy under normal chow feeding conditions. Mice lacking Y1 receptor in the hematopoietic.

Deficiency of adipocyte IKKβ does not affect diet-induced weigh gain but results in an exaggerated diabetic phenotype when challenged with an HFD. A: IKKβ.

Glycemic control and body weight over 52 weeks.

a b c d e f Wankhade et al., Supplementary Figure 1

Presentation transcript:

Effects of Rosi treatment on ASKO mice. Effects of Rosi treatment on ASKO mice. Rosi (0.03%) or vehicle was administered to 6-month-old male WT and ASKO mice for 10 weeks. A: Body weight curve (left) and total fat weight (right) of WT and ASKO mice with or without Rosi. B: Fat pad weight of WT and ASKO mice with or without Rosi. C: H&E staining of subcutaneous WAT from WT and ASKO mice with or without Rosi. Arrows indicate putative newly formed adipocytes. Scale bar is 50 µm. D: Expression of PPAR-γ and its target genes in Epi-WAT. E: Weight changes of BAT in WT and ASKO mice with or without Rosi. F: Plasma total cholesterol (TC), TAG, glucose (GLU) (left), and NEFA (right) in mice fasted for 4 h. Plasma glucose concentrations for glucose tolerance tests (GTT) (G) and insulin tolerance tests (ITT) (H) in mice fasted for 16 h and 4 h, respectively. Area under curve (AUC) is also quantified. Plasma levels of insulin (I), leptin, and adiponectin (J) in mice fasted for 4 h. Values are the mean ± SEM, n = 5–8. *P < 0.05, **P < 0.01, ***P < 0.001 for Rosi diet vs. normal diet (ND). #P < 0.05, ##P < 0.01, ###P < 0.001 for ASKO vs. WT. Lu Liu et al. Diabetes 2014;63:2320-2331 ©2014 by American Diabetes Association